コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 es them impractical for surgical removal and autologous transplantation.
2 of patients with germ cell tumors undergoing autologous transplantation.
3 patients received melphalan 200 mg/m(2) with autologous transplantation.
4 tic syndromes (MDS) have been reported after autologous transplantation.
5 sufficient numbers of normal stem cells for autologous transplantation.
6 n chemotherapy and three after allogeneic or autologous transplantation.
7 amyloidosis who meet functional criteria for autologous transplantation.
8 normal PBSCs could be collected and used for autologous transplantation.
9 tute the hematopoietic compartment following autologous transplantation.
10 ocytic cells resistant to HIV-1 growth after autologous transplantation.
11 tation or use of ANK to purge CML marrow for autologous transplantation.
12 of pulp-dentin regeneration in vivo through autologous transplantation.
13 C expansion and lineage commitment following autologous transplantation.
14 rative medicine, given their feasibility for autologous transplantation.
15 prognostic impact of del(13) observed after autologous transplantation.
16 ration as consolidation therapy after double autologous transplantation.
17 cal to validate their in vivo fate following autologous transplantation.
18 experienced treatment failure with previous autologous transplantation.
19 plications, as these cells could be used for autologous transplantation.
20 tiuxetan was followed by high-dose BEAM and autologous transplantation.
21 ted with rituximab-induced neutropenia after autologous transplantation.
22 ed DLBCL should be considered for RIT versus autologous transplantation.
23 reviously experienced treatment failure with autologous transplantation.
24 ized to chemotherapy for 2.5 years versus an autologous transplantation.
25 was administered a median of 3 months before autologous transplantation.
26 ived allogeneic marrow and one had undergone autologous transplantation.
27 bination of ex vivo genetic manipulation and autologous transplantation.
28 who experience disease recurrence following autologous transplantation.
29 ts (56%) entered into the study proceeded to autologous transplantation.
30 There may be a benefit to graft purging in autologous transplantation.
31 worse for those who had previously undergone autologous transplantation.
32 3, and 48% of patients had undergone a prior autologous transplantation.
33 cies, and ex vivo purging of cancer cells in autologous transplantation.
34 ransplantations, whereas 162 (99%) performed autologous transplantations.
37 remission therapies: intensive chemotherapy, autologous transplantation (ABMT), or allogeneic bone ma
41 arrow function is similar to that seen after autologous transplantation and does not carry the risk f
42 be safely combined with high-dose BEAM with autologous transplantation and has the potential to be m
43 ing the potential utility of these cells for autologous transplantation and possible diagnostic testi
44 pse after disease recurrence following prior autologous transplantation, and 51 patients at high risk
46 l transplantation, tumor cell purging before autologous transplantation, and ex vivo cultures used fo
47 tal of 36 patients were studied (29 received autologous transplantation, and seven received allogenei
48 g as the graft of choice in many centers for autologous transplantation, and with increasing frequenc
51 ith A + G had at least a 90% success rate of autologous transplantation as assessed by neutrophil eng
52 conventional chemotherapy support the use of autologous transplantation as salvage therapy if such pa
53 it from early treatment intensification with autologous transplantation, as indicated by the possibil
56 nts who were treated uniformly with a tandem autologous transplantation-based protocol and were evalu
57 ecome the preferred source of stem cells for autologous transplantation because of the technical adva
62 ant event-free survival advantage to upfront autologous transplantation compared with interferon main
63 erived haematopoietic stem cells followed by autologous transplantation could be used to cure beta-ha
64 eed for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related comp
65 Only the four patients treated after prior autologous transplantation developed acute GVHD (P =.000
69 eukemic stem cells that may be beneficial in autologous transplantation for CML and perhaps other leu
71 les from 12 patients who developed TMN after autologous transplantation for Hodgkin lymphoma or non-H
72 focuses on recent advances in allogeneic and autologous transplantation for mantle cell lymphoma.
73 , from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalizati
74 the chemotherapy group as compared with the autologous-transplantation group was 0.81 (P = 0.20 by t
75 as compared with 38 +/- 6.4 percent for the autologous-transplantation group; and the relative risk
76 ymphoma who experience a recurrence after an autologous transplantation has been considered a hazardo
77 reduce relapse of non-Hodgkin lymphoma after autologous transplantation have included ex vivo stem ce
78 an of five lines of prior therapy, including autologous transplantation in 69%, and 17% of patients w
79 ontribute to multilineage repopulation after autologous transplantation in a clinically relevant larg
80 dopamine neurons for up to 2 years following autologous transplantation in a Parkinson's disease (PD)
82 Particular emphasis is placed on the role of autologous transplantation in first complete remission,
83 dies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few an
86 te the outcome of high-dose chemotherapy and autologous transplantation in patients with diffuse B-ce
87 ell (PBC) rescue has become the mainstay for autologous transplantation in patients with lymphoma, mu
88 primitive progenitors to hematopoiesis after autologous transplantation in the rhesus macaque model.
89 tem cells in up to 10% of donors, precluding autologous transplantation in those donors or substantia
90 use of a short consolidation treatment after autologous transplantation increases the complete respon
92 rrow (BM), followed by ex vivo expansion for autologous transplantation may be less morbid, and more
93 om had progression of disease after previous autologous transplantation (median age 32 years [range 1
98 itical aspects of vascular repair, including autologous transplantation of bone marrow-derived stem c
102 key that developed T-cell lymphoma following autologous transplantation of enriched bone marrow stem
103 replacement therapy (ERT) is withheld before autologous transplantation of gamma-retroviral vector-tr
104 logeneic HSCT from CCR5-deficient donors and autologous transplantation of genetically modified hemat
107 tients receiving high dose chemotherapy with autologous transplantation of hematopoietic stem cell pr
108 ere is considered to be a high potential for autologous transplantation of human dental pulp stem cel
109 ctions of impaired IP-DPSCs, suggesting that autologous transplantation of IFN-gamma-accelerated IP-D
110 st that an HIV vaccine might be delivered by autologous transplantation of in vitro-programmed HSPCs,
113 contribute to HIV cure through allogeneic or autologous transplantation of naturally occurring or eng
114 proach shows definitive engraftment by using autologous transplantation of noninjured recipients, our
117 py has been developed as a method to perform autologous transplantations of a patient's own stem cell
118 cells (HSPCs) from FA patients, either after autologous transplantation or infusion into immunodefici
121 ing in 1994, based on encouraging results in autologous transplantation, patients (n = 81) were treat
123 patient cost in 1997 dollars was $55,500 for autologous transplantation (range, $28,200 to $148,200)
124 ped leukemia at an average of 16 months post-autologous transplantation (range, 11 to 21 months).
125 loma refractory to standard chemotherapy and autologous transplantation received a matched unrelated
128 sing parameters derived from the analysis of autologous transplantation studies in glucose-6-phosphat
130 imulation were applied to limiting-dilution, autologous-transplantation studies in cats heterozygous
132 ercent, P = 0.005) in the group treated with autologous transplantation than in the intensive-chemoth
133 e a potential source of expandable cells for autologous transplantation to treat Parkinson's Disease
135 tients may receive intensive chemotherapy or autologous transplantation; we undertook this randomised
136 non-Hodgkin's lymphoma who were eligible for autologous transplantation were randomized to receive r-
137 honate use, and myeloma therapy, except more autologous transplantations were performed on patients i
138 ted poor outcomes with immunochemotherapy or autologous transplantation will be important in determin
140 reated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 1
142 ute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy.
143 cells by use of antibodies in the setting of autologous transplantation, with emphasis on the emergin
144 generating unlimited quantities of cells for autologous transplantation, with potential application i
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。